HETEROCYCLIC PYRAZOLE DERIVATIVES AS TYPE III RECEPTOR TYROSIKINASE INHIBITORS Russian patent published in 2025 - IPC C07D495/04 A61K31/4162 A61K31/4439 A61K31/5377 A61K31/541 A61K35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (II), (III), (IV) or (V), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. In the above formulas, the values of the variables are as follows: G is selected from a group consisting of an optionally substituted C6-aryl, optionally substituted 5–6 membered heteroaryl having one or more heteroatoms selected from N and S, optionally substituted 5–8 membered heterocyclyl having one or more heteroatoms selected from O and N, C2-C10 alkynyl and a direct bond; L is selected from a group consisting of –CH=, -CHR⁴-, -(CH₂)_q-, -NR⁵-, -O-, -O(CH₂)_q-, -C(O)-, -C(O)(CH₂)_q-, -SO₂- and direct communication, in which each q is individually and independently integer from 1 to 4; Z is selected from the group consisting of hydrogen, deuterium, halogen, C1-C4 alkyl, C1-C4 alkylamine, C1-C4 dialkylamine and optionally substituted 4–7 membered heterocyclyl or a heterocyclic spiro compound; R¹ is selected from a group consisting of hydrogen and deuterium; R² is selected from the group consisting of hydrogen, deuterium, halogen and C1-C6 alkyl; R³ is selected from the group consisting of hydrogen, deuterium and C1-C6 alkyl; R⁴ is selected from the group consisting of deuterium and C1-C6 alkyl; and R⁵ is selected from the group consisting of hydrogen and C1-C6 alkyl. Also disclosed is a pharmaceutical composition containing said compound, and a method of treating using said compound.

EFFECT: disclosed compounds inhibit RTK class III kinases, such as kinases FLT3, PDGFR, and can be used to treat diseases or disorders mediated by such kinases, particularly cancer.

10 cl, 7 tbl, 6 ex